Chronic O-β-N-acetylglucosaminylase inhibition with Thiamet-G prevents tau pathology and hyperactivity in rTg4510 mice
Background: The abnormal hyperphosphorylation of the microtubule-associated protein tau plays a [...]
Alectos Announces Preclinical Data for Novel Cancer Metabolism Target
May 22, 2014 – Alectos today announced publication of preclinical [...]
O-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 pathway
The hexosamine biosynthetic pathway elevates posttranslational addition of O-linked β-N-acetylglucosamine [...]
O-GlcNAc and neurodegeneration: biochemical mechanisms and potential roles in Alzheimer’s disease and beyond
Alzheimer disease (AD) is a growing problem for aging populations [...]
Glucocerebrosidase 2 Gene Deletion Rescues Type 1 Gaucher Disease
The inherited deficiency of the lysosomal glucocerebrosidase (GBA) due to [...]
O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers
The aggregation of the microtubule-associated protein tau into paired helical [...]
Increasing brain protein O-GlcNAcylation mitigates breathing defects and mortality of Tau.P301L mice
The microtubule associated protein tau causes primary and secondary tauopathies [...]
Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy
Neurofibrillary tangles (NFT), mainly consisting of fibrillar aggregates of hyperphosphorylated [...]
Alectos Therapeutics Announces Achievement of Preclinical Milestone in Merck Alzheimer’s Collaboration
Vancouver, British Columbia (November 16, 2012) – Alectos Therapeutics Inc. [...]
O-GlcNAc modification prevents peptide-dependent acceleration of α-synuclein aggregation
Sweet relief: the Parkinson's disease-associated protein α-synuclein is post-translationally modified [...]